Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
One segment earns more than the whole company
Acquisition amortization, impairments and corporate costs sit outside the segments, and together they absorbed more than Orthopaedics earned.
For investorsWhat Stryker's margin depends on when price adds almost nothing
For foundersThe playbook behind selling beside the surgeon
A non-deductible write-down, with higher special charges, turned 7.6% sales growth into a 12.3% fall in net earnings.
Volume supplied nearly all of the quarter's growth, so margin gains rest on mix and cost rather than on pricing.
Free cash flow of $1.22B exceeded net earnings of $753M, because the impairment and amortization charges used no cash.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Stryker Corporation from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
